Abagovomab

Abagovomab is a monoclonal antibody used in the treatment of ovarian cancer

Abagovomab

Other names[edit | edit source]

ACA 125
Anti-idiotype ovarian cancer vaccine
MAb ACA 125
Monoclonal Anti-idiotype Antibody ACA125

Indications[edit | edit source]

Abagovomab is studied as an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer

Mechanism of action[edit | edit source]

A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity.
With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation

Diagram showing stage 3A to 3C ovarian cancer

Manufacturer[edit | edit source]

Abagovomab has been developed by the pharmaceutical company Menarini.

Clinical trials[edit | edit source]

A multicenter clinical trial, internationally known as MIMOSA is being studied. In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with paclitaxel and carboplatin.

Unfortunately, phase III of a trial looking at potential benefit of Abagavomab in patients treated with ovarian cancer showed no benefit in preventing a remission.

Ovarian cancer[edit | edit source]

Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.

Also see[edit | edit source]

External links[edit | edit source]

Abagovomab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.